Pfizer (PFE) has resolved the legal challenge filed by advocacy group Do No Harm to the company's Breakthrough fellowship program, with a New York district court dismissing the case Friday.
According to the court document, Pfizer changed the criteria for the program in February 2023 and has announced that it will no longer accept new applications after the program's fifth and final cohort of fellows.
Do No Harm filed the lawsuit in September 2022, claiming that the program was "racially discriminatory."
Pfizer did not immediately respond to MT Newswires' request for comment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。